Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195830 | 1.00 | VCAM1 (0.44) | VCAM1ARMAOAMAOBFLT1 | |
| SCHEMBL2902333 | 0.84 | KIF11 (0.54) | MAOAMAOBKIF11TDO2HSD11B1 | |
| SCHEMBL30480935 | 0.82 | VCAM1 (0.48) | VCAM1ARMAOAMAOBPDK1 | |
| SCHEMBL234592 | 0.82 | VCAM1 (0.48) | VCAM1ARMAOAMAOBPDK1 | |
| 4-Hydroxybenzaldehyde SCHEMBL27549492 | 0.79 | ALDH5A1 (0.46) | MAOAMAOBFLT1FLT4KDR | |
| SCHEMBL22115304 | 0.79 | GABRG2 (0.52) | PDK2SLC22A12 | |
| SCHEMBL30712417 | 0.79 | GABRG2 (0.52) | PDK2SLC22A12 | |
| SCHEMBL1477679 | 0.79 | CYP11B1 (0.43) | GRM5 | |
| SCHEMBL825866 | 0.78 | VCAM1 (0.53) | VCAM1ARMAOAMAOBFLT1 | |
| SCHEMBL29416796 | 0.78 | EGLN2 (0.44) | GRM5KIF11ALDH1A1EGLN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111668481-B | Preparation method of metal aluminum secondary battery with multi-group organic micromolecules as positive electrode | 北京科技大学 | 2021-12-03 | — | — | CN | claimed |
| CN-111668481-A | Preparation method of metal aluminum secondary battery with multi-group organic micromolecules as positive electrode | 北京科技大学 | 2020-09-15 | — | — | CN | claimed |
| US-5897940-A | Ink jet transparencies | XEROX CORPORATION (US) | 1999-04-27 | — | — | US | claimed |
| US-5744273-A | Laminatable backing substrates containing fluoro compounds for improved toner flow | XEROX CORPORATION (US) | 1998-04-28 | — | — | US | claimed |
| JP-6072980-A | — | — | None | — | — | JP | disclosed |
| WO-2026099466-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-12570799-B2 | Crystalline polyethernitrile | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4678641-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-12378218-B2 | Cyclopentane compounds | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| JP-H0672980-A | PRODUCTION OF 3,4-DIFLUOROBENZONITRILE | ASAHI GLASS CO LTD | 1994-03-15 | — | — | JP | disclosed |
| EP-0270964-B1 | PROCESS FOR OBTAINING SUBSTITUTED FLUOROBENZENES | BAYER AG (DE) | 1992-07-08 | — | — | EP | disclosed |
| US-4868347-A | SOLVENT EXTRACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| US-4704483-A | FLUORINATION WITH POTASSIUM FLUORIDE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4582948-A | VAPOR PHASE CHLORO-DENITRATION REACTION | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
| US-4470930-A | Preparation of nuclear chlorinated aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| US-4351777-A | Preparation of fluorobenzonitriles | RHONE-POULENC INDUSTRIES (FR) | 1982-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378218-B2 | Cyclopentane compounds | CYP11B2, CYP11B1, SQLE | VCAM1 1842/4885AR 2420/4885MAOA 1770/4885 |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | VCAM1 3711/4885AR 2395/4885MAOA 3883/4885 |
| US-12570799-B2 | Crystalline polyethernitrile | AR, NR5A1, ESRRA | VCAM1 3399/4885AR 1/4885MAOA 4330/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | VCAM1 3711/4885AR 2395/4885MAOA 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.